Advertisement
Australia markets closed

  • ALL ORDS

    7,810.10
    -88.80 (-1.12%)
     

  • ASX 200

    7,560.00
    -82.10 (-1.07%)
     

  • AUD/USD

    0.6405
    -0.0021 (-0.32%)
     

  • OIL

    84.39
    +1.66 (+2.01%)
     

  • GOLD

    2,394.90
    -3.10 (-0.13%)
     

  • Bitcoin AUD

    96,872.25
    +1,316.23 (+1.38%)
     

  • CMC Crypto 200

    1,283.18
    -29.45 (-2.24%)
     

  • AUD/EUR

    0.6019
    -0.0011 (-0.19%)
     

  • AUD/NZD

    1.0883
    +0.0008 (+0.07%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,135.68
    -250.19 (-1.53%)
     

  • NIKKEI 225

    37,139.63
    -940.07 (-2.47%)
     

Fresenius SE KGaA Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St
·1-min read

Fresenius SE KGaA (ETR:FRE) Third Quarter 2022 Results

Key Financial Results

  • Revenue: €10.5b (up 12% from 3Q 2021).

  • Net income: €321.0m (down 22% from 3Q 2021).

  • Profit margin: 3.1% (down from 4.4% in 3Q 2021). The decrease in margin was driven by higher expenses.

  • EPS: €0.57 (down from €0.74 in 3Q 2021).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Fresenius SE KGaA Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 22%.

Looking ahead, revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany.

ADVERTISEMENT

Performance of the German Healthcare industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Fresenius SE KGaA, and understanding it should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here